NDMA Exposure Cancer Risk
If you or a loved one was prescribed a medication containing valsartan and subsequently suffered from an injury, you may qualify to participate in the valsartan lawsuit.
Contact TorHoerman Law for a free no-obligation case consultation with a valsartan injury lawyer today.
You can also use our chatbot to receive a free, instant online case evaluation to find out if you qualify for compensation right away.
Valsartan is an off-patent active ingredient in a number of generic drugs.
Valsartan is commonly present in drugs used to treat:
Valsartan is classified as an angiotensin receptor blocker (ARB).
Valsartan works by relaxing blood vessels, allowing blood to flow more easily.
Valsartan is also sometimes prescribed with hydrochlorothiazide (HCTZ) to treat hypertension.
Valsartan has been associated with an increased risk of developing:
Along with the most serious dangers of taking valsartan, there are a number of side effects associated with valsartan.
Chinese manufacturer Zhejiang Huahai Pharmaceutical first discovered that the generic valsartan products that the company was producing contained impurities, including N-nitrosodimethylamine (NDMA).
Zhejiang Huahai Pharmaceutical supplied these generic drugs containing NDMA to US-based pharmaceutical companies Major Pharmaceuticals, Solco Healthcare, and Teva Pharmaceuticals Industries Ltd. These companies then processed and distributed the drugs to the US market.
NDMA is a semivolatile organic chemical that forms in both industrial and natural processes.
It is member of N-ni- trosamines, a family of potent carcinogens (EPA).
Based on lab testing, NDMA is classified as a probable human carcinogen. NDMA is found naturally and at low levels in water and foods such as meats, dairy, and vegetables.
Extremely small levels of NDMA found in foods are not harmful. However, higher levels of NDMA are associated with an increased risk of a number of serious cancers and liver damage.
NDMA contamination in valsartan is high enough that it has sparked major concern from manufacturers, federal oversite institutions, and consumers. While NDMA has not yet been labeled a known human carcinogen, it is still likely to be dangerous to humans.
Due to the presence of the probable carcinogen NDMA in Valsartan, Valsartan could put consumers at risk of developing cancer.
Individuals involved in the Valsartan lawsuit claim that NDMA in Valsartan caused them to develop cancer, specifically:
Valsartan is difficult to metabolize, often causing stress on the liver. Valsartan has been linked to an increased risk of developing kidney cancer. This is due to the presence of NDMA, which is a probable carcinogen found in valsartan.
Studies of NDMA consumption in animals has linked the chemical to an increased risk of kidney cancer specifically.
Because of the presence of NDMA in Valsartan, the drug could put consumers at risk of kidney disease.
If you or a loved one took valsartan and subsequently were diagnosed with kidney damage or cancer of the kidney, you may qualify for a valsartan lawsuit.
NDMA has been linked to an increased risk of liver disease & liver damage when consumed. Valsartan can cause liver damage in consumers. Valsartan also increases the risk of developing liver cancer.
If you or a loved one took valsartan and subsequently were diagnosed with liver damage or liver cancer, you may qualify for a valsartan lawsuit.
In July 2018, the U.S. Food and Drug Administration (FDA) issued a recall of a number of pharmaceutical drugs containing valsartan used to treat hypertension (high blood pressure) and heart failure due to the increased risk of certain cancers associated with NDMA.
Not all drugs containing valsartan were named in the recall.
“We have carefully assessed the valsartan-containing medications sold in the United States, and we’ve found that the valsartan sold by these specific companies does not meet our safety standards. This is why we’ve asked these companies to take immediate action to protect patients,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research.
The FDA issued a press release along with the recall announcement – “The presence of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured,” the FDA release said.
The FDA is now conducting a full-length investigation into the safety of the recalled products.
The FDA stresses the importance that patients DO NOT stop taking the recalled products altogether – the danger of abruptly discontinuing the use of this medication greatly outweighs the risks associated with short-term NDMA exposure – patients should rather contact their healthcare provider right away to discuss alternative medication options.
22 other countries that had previously recalled valsartan products prior to the FDA valsartan recall.
The following were named in the recall:
A valsartan lawsuit was filed on behalf of individuals who were prescribed valsartan and subsequently suffered injuries related to NDMA consumption.
Claims are being investigated against manufacturers and distributors of hypertension medications containing the active ingredient valsartan, which contains the probable human carcinogen N-nitrosodimethylamine (NDMA).
Major Pharmaceuticals, Solco Healthcare, and Teva Pharmaceuticals Industries Ltd. sold hypertension and heart failure medication containing valsartan, putting consumers at risk of developing a number of life-threatening cancers.
Tor Hoerman Law is currently accepting new valsartan lawsuit clients.
Were you prescribed one or more of the following products?
And developed any of the following injuries as a result?
If so, you may be eligible to participate in a valsartan lawsuit. You should contact an experienced valsartan injury lawyer right away to discuss the specifics of your case.
Contact TorHoerman Law for a free, no-obligation case consultation to discuss your legal options today.
Want to find out if you qualify right away? Use our chatbot below to receive a free, instant online case evaluation right now.
2 steps you should take before filing a valsartan NDMA lawsuit:
The first step you should take before initiating legal action is mitigating damages you suffer as a result of your injuries.
In order to mitigate damages, you should seek medical attention as soon as possible after your injury. Be sure to get an official diagnosis from your doctor & follow your doctor’s orders.
Do everything in your power to decreases the damages that you incur as a result of your injury. This is a crucial step in building a strong & honest case.
After you have seen a doctor, you should consider contact a lawyer to represent you. Before doing so, familiarize yourself with the steps of civil litigation, so that you are aware of the process of a valsartan lawsuit. Once you know what legal action entails, contact an attorney to discuss your legal options.
Do not hesitate to contact a valsartan injury lawyer – the statute of limitations limits the amount of time you have to take legal action after an injury, so if you wait too long, you may be barred from using the courts.
There are many benefits of hiring a personal injury attorney to represent you.
Your valsartan injury lawyer will be
Let a valsartan injury lawyer handle your case so that you can focus on what really matters, recovery.
Our team of attorneys has more than 100 years of litigation experience. With more than $4 billion in negotiated settlements and verdicts for our clients, our results speak for themselves.
TorHoerman Law, we offer free no-obligation case consultations with all potential valsartan lawsuit clients. Call today to discuss your case with a valsartan injury lawyer today.
All TorHoerman Law valsartan injury lawyers work on a contingency fee basis. So, we are just as dedicated as our clients to getting the best possible outcome for all of our valsartan lawsuit plaintiffs. Any questions? Don’t hesitate to contact us.
Both Valsartan and Losartan are classified as angiotensin receptor blockers (ARBS).
Although they have the same classification, losartan and valsartan are not the same.
There are a number of notable differences.
Notable differences include:
Due to the presence of NDMA, classified as a probable carcinogen which has shown to cause liver damage in animal studies, valsartan could cause negative health effects to a consumer, including liver damage.
Due to the presence of NDMA, classified as a probable carcinogen linked to kidney cancer, NDMA could cause negative health effects to a consumer, including kidney disease.
The FDA announced a recall of several drugs containing valsartan in July 2018 due to the presence of known carcinogen NDMA found in valsartan.
Valsartan has been linked to increased risks of with an increased risk of liver cancer, kidney cancer, stomach cancer, and cancer of the intestines.
Valsartan is an off-patent active ingredient in a number of generic drugs, including drugs used to treat hypertension, heart failure, left ventricular failure, and left ventricular dysfunction following myocardial infarction.